Skip to main content
. 2024 Mar 21;13(6):1819. doi: 10.3390/jcm13061819

Figure 2.

Figure 2

Response to brolucizumab therapy in a treatment-naïve patient with diabetic macular edema (DME) assessed by optical coherence tomography (OCT). Left eye of a 73-year-old woman with severe nonproliferative diabetic retinopathy (NPDR) on fundus photography (upper left panel) and on fluorescein angiography (lower left panel) with intraretinal fluid (IRF) and hyperreflective foci on OCT (right panel) with a resolved center-involving DME after 2 injections q6w (week 12) and a complete regression of IRF after 3 injections (week 18), which was maintained throughout the upload (week 24) and the patient was extended to q12 w (week 36).